|
|
Weekly Digest
June 9, 2026
Volume 3, Issue 2
|
|
What’s Inside This Week
Enforcement and accountability dominated the past week, led by a Federal Trade Commission lawsuit against multilevel marketer Amare Global over claims that its supplements could treat depression, anxiety and ADHD in children. The theme carried through a newly approved $90 million settlement closing more than a decade of Joint Juice litigation, and an expanded Salmonella recall of moringa capsules sold at major retailers, each a reminder of the substantiation and safety obligations DSHEA places on manufacturers. On the policy front, the National Animal Supplement Council pressed its Animal Health Supplement Act to bring pet supplements under a formal FDA framework. And in the longevity category, a Nature Metabolism study questioned whether blood NAD+ means anything for aging, injecting fresh scientific skepticism into the booming NMN and NAD+ market even as Japanese firms and ingredient suppliers double down on healthy-aging science.
|
|
|
|
FDA & Regulatory Enforcement
|
|
FTC sues Amare over mental-health supplement claims
NutraIngredients · June 4, 2026
The Federal Trade Commission sued multilevel marketer Amare Global Holdings and three executives on June 2, alleging the company illegally marketed supplements, including Kids Happy Juice and Kids Mood+, as treatments for depression, anxiety and ADHD in children and adults. The complaint targets gut-brain axis and “clinically proven” claims spread across social media, signaling intensifying FTC scrutiny of structure/function marketing that crosses into disease claims. For an industry operating under DSHEA, the case is a reminder that supplements positioned as treatments invite enforcement well beyond label technicalities.
|
|
|
After 12 years, Joint Juice litigation ends with $90M in settlements
NutraIngredients · June 9, 2026
A California court granted final approval to roughly $90 million in settlements resolving more than a decade of class action litigation over Joint Juice glucosamine and chondroitin claims. Plaintiffs argued the products’ joint-health representations were not supported by scientific evidence, and a New York jury had earlier found the labeling deceptive. Legal observers warn that DSHEA structure/function claims offer no protection when courts find the overall label misleading, underscoring the need for rigorous, independent substantiation.
|
|
|
|
|
Legislation & Policy
|
|
NASC pushes Animal Health Supplement Act to modernize oversight
NutraIngredients · June 8, 2026
The National Animal Supplement Council is advancing the Animal Health Supplement Act, legislation it helped draft to give pet supplements a formal FDA framework modeled on NASC’s existing voluntary standards. The bill would codify GMP requirements, mandate labeling and registration, and grandfather current ingredients while establishing a safety-notification pathway similar to the one used for human dietary supplements under DSHEA. NASC concedes that passage faces headwinds from a midterm-shortened congressional session.
|
|
|
|
|
NMN, NAD+ & the Longevity Market
|
|
Blood NAD+ may not be a useful biomarker of aging after all
NutraIngredients · June 2, 2026
A study in Nature Metabolism reported that whole-blood NAD+ levels stayed stable across age groups and lifestyle interventions, challenging the premise that the molecule can serve as a reliable blood biomarker of aging. Researchers cautioned that rising circulating NAD+ after NMN or NR supplementation reflects pharmacodynamic engagement rather than proof of improved healthspan. The findings, also covered by The New York Times, add scientific friction to a fast-growing longevity-supplement category that increasingly depends on NMN, an ingredient the FDA only recently confirmed as lawful under DSHEA.
|
|
|
Major Japanese firms to drive industry-government-academia longevity partnerships
NutraIngredients · June 9, 2026
Major Japanese companies are forming industry, government and academia partnerships to accelerate longevity research and commercialization, signaling deepening corporate investment in the healthy-aging market. The collaborations point to a maturing global pipeline of longevity ingredients that US supplement brands increasingly compete with and source from. For DSHEA-regulated marketers, the trend raises both the commercial opportunity and the bar for credible scientific substantiation.
|
|
|
|
|
Ingredient Science & Research
|
|
Krill oil outperforms fish oil in raising fatty-acid plasma, with sex effects
NutraIngredients · June 9, 2026
New research found krill oil raised plasma fatty-acid levels more effectively than fish oil, with effects that differed by sex. The omega-3 findings could influence formulation and comparative claims in the crowded cardiovascular and healthy-aging categories. Bioavailability head-to-heads like this increasingly shape how marketers substantiate the structure/function claims permitted under DSHEA.
|
|
|
OmniActive ingredient boosts cognitive performance when paired with caffeine
NutraIngredients · June 9, 2026
A study reported that an OmniActive botanical ingredient enhanced cognitive performance when combined with caffeine, supporting growing demand for nootropic and focus formulations. Ingredient-plus-stimulant pairings are a popular route to differentiated claims, though regulators expect substantiation that matches the specific benefit advertised. The data illustrate how branded-ingredient research underpins compliant claim-making in the supplement market.
|
|
|
Spinach extract one step closer to satiety health claim
NutraIngredients · June 8, 2026
A spinach extract moved a step closer to an approved satiety-related health claim, reflecting continued scientific interest in appetite and weight-management ingredients. Claim evaluations abroad often inform how US marketers frame the structure/function statements allowed under DSHEA. The development lands as weight-management remains one of the most competitive and closely watched supplement categories.
|
|
|
|
|
Industry & Deals
|
|
Ingredion strengthens functional-fiber portfolio with Benicaros acquisition
NutraIngredients · June 4, 2026
Ingredion acquired the prebiotic fiber ingredient Benicaros, strengthening its functional-fiber portfolio amid surging interest in gut and immune health. The deal reflects continued consolidation around science-backed ingredients that supplement and functional-food brands can build claims around. Strategic acquisitions like this shape the ingredient supply chain that DSHEA-regulated finished products depend on.
|
|
|
|
|
Safety & Recalls
|
|
Company expands recall of moringa supplements linked to Salmonella outbreak
The Epoch Times · June 3, 2026
New York-based Total Nutrition expanded its recall of TNVitamins and Doctor’s Pride moringa capsules over possible Salmonella contamination, per an FDA notice published June 3. The affected products were sold through major retailers including Walmart, Amazon, Target and TikTok Shop. The expansion extends a multistate outbreak investigation and highlights the supply-chain and GMP responsibilities that DSHEA places on supplement manufacturers.
|
|
|
Your Voice Matters
The FDA is weighing how to redefine the scope of dietary supplement ingredients, a decision that could reshape DSHEA for a generation. The agency is taking input from industry and the public. Make sure the preservation of DSHEA is part of that conversation.
Make Your Voice Heard
|
|
|
DSHEA Preservation Alliance
Defending the Dietary Supplement Health and Education Act since 1994.
© 2026 DSHEA Preservation Alliance. All rights reserved.
|
